Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. (More)
Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S.
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. (More)
Zeidner JF, Foster MC, Blackford AL, et al.
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. (More)
Park IK, Mundy-Bosse B, Whitman SP, et al.
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. (More)
Boysen J, Sinha S, Price-Troska T, et al.